Zevra Therapeutics(ZVRA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates FDA approval of MIPLYFFATM and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra received rare pediatric disease Priority Review Voucher Company ends quarter with cash, cash equivalents and investments of $95.5 million Company to host conference call and webcast today, Nov. 12, 2024, 4:30 p.m. ET CELEBRATION, Fla., Nov. 12, 2024 -- Zevra Therapeutics, In ...